SCHEMBL4487606

SCHEMBL4487606

Cc1ccc(-c2c3ccccc3nn2Cc2ccccc2Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 5/20 0.56
NR1H3 Q13133 5/20 0.56
LMNA P02545 2/20 0.49
ALDH1A1 P00352 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
GAA P10253 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
P2RY14 Q15391 1/20 0.45
CNR2 P34972 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
ALOX5AP P20292 1/20 0.44
NR1I2 O75469 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489322 0.86 NR1H2 (0.46) NR1H2NR1H3LMNAALDH1A1POLB
SCHEMBL4479319 0.84 SMN1; SMN2 (0.52) NR1H2NR1H3LMNAALDH1A1MEN1
SCHEMBL4494497 0.83 ALDH1A1 (0.53) NR1H2NR1H3LMNAALDH1A1L3MBTL1
SCHEMBL4482187 0.82 NR1H2 (0.52) NR1H2NR1H3LMNAALDH1A1TDP1
SCHEMBL27669279 0.78 CYP1A2 (0.49) NR1H2NR1H3LMNAALDH1A1POLB
SCHEMBL4476567 0.78 MAPT (0.58) NR1H2NR1H3ALDH1A1POLBMEN1
SCHEMBL4480794 0.77 RORC (0.54) NR1H2NR1H3LMNAALDH1A1L3MBTL1
SCHEMBL4478557 0.76 HTT (0.56) LMNAALDH1A1L3MBTL1POLBTDP1
SCHEMBL5245419 0.74 NR1H2 (0.69) NR1H2NR1H3MEN1KMT2ANR1I2
SCHEMBL27669283 0.74 NR1H2 (0.42) NR1H2NR1H3LMNAPOLBNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514465-B2 Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-04-07 US disclosed
EP-1659115-A1 Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents Yung Shin Pharm. Ind. Co., Ltd. (TW) 2006-05-24 EP disclosed
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents FLT4, FLT1, KDR NR1H2 3809/4885NR1H3 3609/4885LMNA 3368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.